4//SEC Filing
You Angie 4
Accession 0001415889-24-005545
CIK 0001825367other
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 5:10 PM ET
Size
8.8 KB
Accession
0001415889-24-005545
Insider Transaction Report
Form 4
RayzeBio, Inc.RYZB
You Angie
Director
Transactions
- Disposition to Issuer
Employee Stock Option (right to buy)
2024-02-26−73,731→ 0 totalExercise: $3.24Exp: 2032-03-21→ Common Stock (73,731 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2024-02-26−40,848→ 0 totalExercise: $3.24Exp: 2032-11-30→ Common Stock (40,848 underlying)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated as of December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").
- [F2]At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.
Documents
Issuer
RayzeBio, Inc.
CIK 0001825367
Entity typeother
Related Parties
1- filerCIK 0001647664
Filing Metadata
- Form type
- 4
- Filed
- Feb 26, 7:00 PM ET
- Accepted
- Feb 27, 5:10 PM ET
- Size
- 8.8 KB